Logo

Pfizer and BioNTech Report Results of Omicron BA.4/BA.5-Adapted Bivalent Booster for the Treatment of COVID-19

Share this

Pfizer and BioNTech Report Results of Omicron BA.4/BA.5-Adapted Bivalent Booster for the Treatment of COVID-19

Shots:

  • The company reported the new results of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine against Omicron sublineages, incl. BA.4.6, BA.2.75.2, BQ.1.1 & XBB.1
  • The results showed that the bivalent vaccine booster elicited a greater increase in neutralizing Ab titers over the original COVID-19 vaccine, neutralizing Ab titers against Omicron sublineages BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 increased 4.8 to 11.1 fold from pre-booster levels, following a 30µg booster dose of the bivalent vaccine while 1.5 to 2.3 fold, following a booster dose of COVID-19 vaccine
  • The booster dose of the bivalent vaccine has been authorized in the US for emergency use in patients aged ≥5yrs. & received EC’s marketing authorization in the EU

Ref: Pfizer | Image: BioNTech

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions